Adverse events were experienced in 28% of participants, though they were both transient and mild in nature. Long-term reduction in symptom severity was associated with an increase in QOL, achieved in up to 64% of respondents at week-52 when compared to baseline. IBS symptom severity reduction was achieved in up to 61% of respondents at week-12, 64% of respondents at week-24, and maintained in up to 75% of respondents at week-52.

Sixty participants diagnosed with IBS received the six-month FMT treatment. Wilcoxon matched-pairs signed-rank tests were conducted to compare differences in abdominal symptom and SF-36 QOL scores over the follow-up timepoints. Validated abdominal symptoms and Short-Form (SF-36) Quality of Life (QOL) questionnaires were collected at baseline, week-12, week-24, and week-56, respectively. Participants received one colonoscopically delivered FMT followed by 36 rectal enemas across a six-month period. Patients diagnosed with IBS confirmed by Rome IV Criteria were recruited for single-centre, single-arm, prospective clinical observational study. To evaluate the safety and efficacy of a novel six-month FMT treatment protocol in IBS.

The use of multiple FMT infusions is one proposed mechanism through which the efficacy of FMT can be amplified. The use of faecal microbiota transplantation (FMT) in irritable bowel syndrome (IBS) has frequently failed to induce long-term symptomatic improvement.

Graphpad prism 5